More recently, we demonstrated that ADI-PEG20 is well tolerated and has promising clinical potential in combination with chemotherapy in a phase I study of recurrent high-grade gliomas that are arginine auxotrophic and ASS1 deficient (22). This evidence concerns the gene ASS1 and central nervous system cancer.